Terms: = Lymphoma AND CARD11, BIMP3, 84433, ENSG00000198286, CARMA1, MGC133069, Q9BXL7 AND Treatment
54 results:
1. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
Geng H; Jia S; Zhang Y; Li J; Yang Q; Zeng L; Zong X; Lu Y; Lu S; Zhou J; Li C; Wu D
Front Immunol; 2023; 14():1219167. PubMed ID: 37671152
[TBL] [Abstract] [Full Text] [Related]
2. Dimethyl Fumarate Suppresses the Proliferation of HTLV-1-infected T Cells by Inhibiting CBM Complex-triggered NF-B Signaling.
Sato T; Maeta T; Ito S
Anticancer Res; 2023 May; 43(5):1901-1908. PubMed ID: 37097671
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological and molecular genetic characteristics of primary gastric follicular lymphoma.
Kim H; Shin D; Son SM; Cho J; Kim JE; Kim Y; Jeon T; Ko YH
Hum Pathol; 2023 Jun; 136():114-122. PubMed ID: 37054783
[TBL] [Abstract] [Full Text] [Related]
4. Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.
Kameda T; Kataoka K; Kamiunten A; Hidaka M; Miyoshi H; Nakano N; Nosaka K; Yoshimitsu M; Yasunaga JI; Kogure Y; Shide K; Miyahara M; Sakamoto T; Akizuki K; Hidaka T; Kubuki Y; Koya J; Kawano N; Yamashita K; Kawano H; Toyama T; Maeda K; Marutsuka K; Imaizumi Y; Kato K; Sugio T; Tokunaga M; Tashiro Y; Takaori-Kondo A; Miyazaki Y; Akashi K; Ishitsuka K; Matsuoka M; Ohshima K; Watanabe T; Kitanaka A; Utsunomiya A; Ogawa S; Shimoda K
Haematologica; 2023 Aug; 108(8):2178-2191. PubMed ID: 36794502
[TBL] [Abstract] [Full Text] [Related]
5. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
[TBL] [Abstract] [Full Text] [Related]
6. Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis.
Coombes C; Horikawa K; Jain S; Jiang S; Lim JH; Saxena K; Shadbolt B; Smyth L; Tobin J; Talaulikar D
Pathology; 2023 Feb; 55(1):104-112. PubMed ID: 36420560
[TBL] [Abstract] [Full Text] [Related]
7. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, treatment and Prognosis of Primary Central Nervous System lymphoma.
Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
[TBL] [Abstract] [Full Text] [Related]
8. Hyper-IgE and Carcinoma in CADINS Disease.
Pietzsch L; Körholz J; Boschann F; Sergon M; Dorjbal B; Yee D; Gilly V; Kämmerer E; Paul D; Kastl C; Laass MW; Berner R; Jacobsen EM; Roesler J; Aust D; Lee-Kirsch MA; Snow AL; Schuetz C
Front Immunol; 2022; 13():878989. PubMed ID: 35651609
[TBL] [Abstract] [Full Text] [Related]
9. Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell lymphomas.
Kim SJ; Kim YJ; Yoon SE; Ryu KJ; Park B; Park D; Cho D; Kim HY; Cho J; Ko YH; Park WY; Kim WS
Cancer Res Treat; 2023 Jan; 55(1):291-303. PubMed ID: 35240014
[TBL] [Abstract] [Full Text] [Related]
10. Clinical and Immunological Features of Human BCL10 Deficiency.
Garcia-Solis B; Van Den Rym A; Pérez-Caraballo JJ; Al-Ayoubi A; Alazami AM; Lorenzo L; Cubillos-Zapata C; López-Collazo E; Pérez-Martínez A; Allende LM; Markle J; Fernández-Arquero M; Sánchez-Ramón S; Recio MJ; Casanova JL; Mohammed R; Martinez-Barricarte R; Pérez de Diego R
Front Immunol; 2021; 12():786572. PubMed ID: 34868072
[TBL] [Abstract] [Full Text] [Related]
11. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
Balasubramanian S; Hodkinson B; Schuster SJ; Fowler NH; Trotman J; Hess G; Cheson BD; Schaffer M; Sun S; Deshpande S; Vermeulen J; Salles G; Gopal AK
Cancer Med; 2022 Jan; 11(1):61-73. PubMed ID: 34791836
[TBL] [Abstract] [Full Text] [Related]
12. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
Seshadri MR; Melnick AM
Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
[TBL] [Abstract] [Full Text] [Related]
13. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract] [Full Text] [Related]
14. The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.
Wang H; Zhang W; Yang J; Zhou K
Hematol Oncol; 2021 Dec; 39(5):605-615. PubMed ID: 34651869
[TBL] [Abstract] [Full Text] [Related]
15. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE; Burger JA
Front Immunol; 2021; 12():689472. PubMed ID: 34177947
[TBL] [Abstract] [Full Text] [Related]
16. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Pedrosa L; Fernández-Miranda I; Pérez-Callejo D; Quero C; Rodríguez M; Martín-Acosta P; Gómez S; González-Rincón J; Santos A; Tarin C; García JF; García-Arroyo FR; Rueda A; Camacho FI; García-Cosío M; Heredero A; Llanos M; Mollejo M; Piris-Villaespesa M; Gómez-Codina J; Yanguas-Casás N; Sánchez A; Piris MA; Provencio M; Sánchez-Beato M
Sci Rep; 2021 Jan; 11(1):1886. PubMed ID: 33479306
[TBL] [Abstract] [Full Text] [Related]
17. Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
Magnes T; Wagner S; Thorner AR; Neureiter D; Klieser E; Rinnerthaler G; Weiss L; Huemer F; Zaborsky N; Steiner M; Weis S; Greil R; Egle A; Melchardt T
ESMO Open; 2021 Feb; 6(1):100012. PubMed ID: 33399078
[TBL] [Abstract] [Full Text] [Related]
18. Development of molecular intervention strategies for B-cell lymphoma.
Zhou W; Chen W
Expert Rev Hematol; 2021 Feb; 14(2):241-252. PubMed ID: 33263441
[TBL] [Abstract] [Full Text] [Related]
19. Adaptive T-cell immunity controls senescence-prone MyD88- or card11-mutant B-cell lymphomas.
Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
[TBL] [Abstract] [Full Text] [Related]
20. Optimization of the
Quancard J; Simic O; Pissot Soldermann C; Aichholz R; Blatter M; Renatus M; Erbel P; Melkko S; Endres R; Sorge M; Kieffer L; Wagner T; Beltz K; Mcsheehy P; Wartmann M; Régnier CH; Calzascia T; Radimerski T; Bigaud M; Weiss A; Bornancin F; Schlapbach A
J Med Chem; 2020 Dec; 63(23):14594-14608. PubMed ID: 33216547
[TBL] [Abstract] [Full Text] [Related]
[Next]
